1Zimmer P,Alberti KG,Shaw J.Global and societal implications of the diabetes epidemic[J].Nature 2001; 414:782 ～ 787.
2Amos A,McCarty D,Zimmet P.The rising global burden of diabetes and its complications:estimates and projections to the year 2010.Diabet Med 1997; 14:S 1 ～ S85.
3King H,Aubert R,Herman W.Global burden of diabetes,1995 -2025:prevalence,numerical estimates and projections[J].Diabetes.Care 1998; 21:1414～ 1431.
4UK Prospective Dabetes Study (UKPDS34) Group.Effect of intensive bolld-glucose control with metforlnin on complications in overweight patients with type 2 diabetes (UKPDS34)[J].Lancet 1998; 352:854～ 865.
5UK Drospective Dabetes Study (UKPDS34) Group.Intensive bloodgluose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPD33)[J].Lancet 1998; 352:837 ～ 853.
6Pan XR,Li GW,Hu YH,et al.Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance:the Da Qing IGT and Diabetes Stud[J].Diabetes Care 1997; 20:537 ～544.
7Tuomilehto J,Lindstrom J,Eriksson JG,et al.Prevention of type 2diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance[J].N Engl J Med 2001; 344:1343 ～ 1350.
8Knowler WC,Barrett-Connor E,Fowler SE,et al.Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformi[J].N Engl J Med 2002; 346:393 ～403.
9The Diabetes Prevention Program.Design and methods for a clinical trial in the prevention of type 2 diabetes[J].Diabetes Care 1999; 22:623～ 634.
10Kirpichnikov D,McFarlane SI,Sowers JR.Mefforlnin:an update.Ann Intern Med 2002; 137:25 -33.
